1. Introduction {#sec1-ijerph-13-00642}
===============

The adverse effects of air pollution on human health are of increasing concern throughout the world \[[@B1-ijerph-13-00642],[@B2-ijerph-13-00642]\]. Air pollution is a complex mixture of particulate and gaseous components. The major particulate matter components are PM~2.5~ (fine particles) and PM~10~ (thoracic particles), which can be classified by aerodynamic diameter. Carbon monoxide (CO), nitrogen dioxide (NO~2~), sulfur dioxide (SO~2~) and ozone (O~3~) are the main gaseous pollutants. In recent years, numerous studies have researched the health effects of air pollution and cardiovascular disease (CVD) has caused extensive concern. Some large epidemiological and observational studies have shown that air pollution has adverse effects on cardiovascular health \[[@B3-ijerph-13-00642],[@B4-ijerph-13-00642],[@B5-ijerph-13-00642]\]. CVD is related to significant morbidity in industrialized countries \[[@B6-ijerph-13-00642]\]. Furthermore, it is the leading cause of death globally \[[@B7-ijerph-13-00642]\].

Cardiac arrhythmia, also called cardiac dysrhythmia, is defined as any change from the normal sequence of electrical impulses. In 2014, 2%--3% of the population in Europe and North America experienced atrial fibrillation \[[@B8-ijerph-13-00642]\]. About 50% of deaths due to CVD and 15% of all deaths are caused by sudden cardiac death, while approximately 80% of sudden cardiac deaths are due to ventricular arrhythmias \[[@B9-ijerph-13-00642]\]. Arrhythmia has distinct characteristics. It could lead to multiple complications. Therefore, identifying the risk factors and taking measurements are significant for decreasing burden of arrhythmia. The incidence of serious air pollution problems have increased in low-income and middle-income countries in recent years. Research has confirmed that economic development and pollution have an inverted-U relationship \[[@B10-ijerph-13-00642]\]. In other words, economic levels reflect the concentrations of air pollution to some degree. However, whether pollutant concentrations influence the threshold of adverse effects is unknown. Therefore, exploring the impact of pollutant concentrations on the relationship between air pollution and arrhythmia is a meaningful issue. In addition, studies conducted in different geographical locations have generally yielded inconsistent results. Therefore, the association on regional variations needs to be evaluated. The association between air pollution and arrhythmia remains controversial \[[@B11-ijerph-13-00642]\]. A series of studies have focused on the association between air pollution and specific types of CVD \[[@B12-ijerph-13-00642],[@B13-ijerph-13-00642],[@B14-ijerph-13-00642]\]. However, there is no systematic review and meta-analysis investigating the association in any language. Therefore, we conducted a comprehensive and systematic review to provide global evidence on the transient association between air pollution and cardiac arrhythmia.

2. Materials and Methods {#sec2-ijerph-13-00642}
========================

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) were followed in the systematic review and meta-analysis \[[@B15-ijerph-13-00642]\]. The protocol was published online at the PROSPERO (registration number: CRD42016032635).

2.1. Databases {#sec2dot1-ijerph-13-00642}
--------------

PubMed, Embase, Global Health, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Web of Science were systematically searched using the following terms: "arrhythmia", "dysrhythmia", "air pollution", "particulate matter", "ozone", "carbon monoxide", "nitrogen dioxide" and "sulfur dioxide"([Supplementary material Table S1](#app1-ijerph-13-00642){ref-type="app"}). We limited our search to studies from inception to 20 June 2015, with no language restrictions. We also manually searched the reference lists of included studies and relevant reviews to identify remaining studies.

2.2. Selection of Articles and Extraction of Data {#sec2dot2-ijerph-13-00642}
-------------------------------------------------

Case-crossover and time-series studies were included if they evaluated the short-term (up to seven days) association between air pollutants (gaseous pollutants: carbon monoxide, nitrogen dioxide, sulfur dioxide, or ozone; particulate components: PM~2.5~ or PM~10~) and arrhythmia hospitalization or mortality. However, studies were excluded if they collected arrhythmia data using implantable cardioverter defibrillator (ICD), home monitors and other equipments. In addition, studies investigating arrhythmia as comorbidity were also excluded. Arrhythmia consists of the following types: atrial fibrillation, bradycardia, conduction disorders, premature contraction, tachycardia, ventricular fibrillation and other rhythm disorders \[[@B16-ijerph-13-00642]\]. Studies investigating arrhythmia or specific types of arrhythmia were all included. Two investigators (Xuping Song and Yu Liu) independently retrieved titles and abstracts to identify eligible studies. Studies that could not be determined by titles and abstracts were selected by full-text screening. Any conflicts were adjudicated by a third investigator (Jinhui Tian). Authors were contacted for any uncertainty. Study characteristics were extracted using a standardized form including the following items: author, year of publication, location, period, study design, population age, outcome, air pollutants, number of events and data source.

2.3. Study Design {#sec2dot3-ijerph-13-00642}
-----------------

We included both case-crossover and time-series studies. The two techniques have their advantages and disadvantages. Case-crossover compares exposure in a case period when the event occurred with exposure in a specified control period. In this technique, cases serve as their own control, which can control stable subject-specific covariates, as well as seasonal patterns and secular trends using a time-stratified approach \[[@B17-ijerph-13-00642]\]. However, it assumes that time-varying risk factors are constant within reference periods. Therefore, case-crossover design is more useful in evaluating acute or transient effects \[[@B18-ijerph-13-00642]\]. Time-series design estimates the association between exposure and outcome using regression analysis. It could effectively control confounding factors. However, the selection used to control secular trends is not robust.

2.4. Data Synthesis {#sec2dot4-ijerph-13-00642}
-------------------

Relative risk (RR) was used as effect estimates in our study. It was converted to a standardized increment of pollutant concentration as follows: 10 μg/m^3^ for PM~2.5~ and PM~10~, 1 ppm for CO, 10 ppb for O~3~, NO~2~ and SO~2~. These levels have been commonly used in previous studies. The following formula was used to calculate the standardized risk estimates: $$\text{RR}_{(\text{standardized})} = \text{RR}_{(\text{original})}^{\text{Increment}{(10)}/\text{Increment}{(\text{original})}}$$

Five studies did not offer overall risk, while stratified risk estimates by age \[[@B19-ijerph-13-00642]\], location \[[@B20-ijerph-13-00642]\] and temperature \[[@B21-ijerph-13-00642],[@B22-ijerph-13-00642],[@B23-ijerph-13-00642]\] were reported. In this case, the stratified estimates were pooled. Five studies \[[@B24-ijerph-13-00642],[@B25-ijerph-13-00642],[@B26-ijerph-13-00642],[@B27-ijerph-13-00642],[@B28-ijerph-13-00642]\] belonged to a subset, and the latest study \[[@B27-ijerph-13-00642]\] was included. One study \[[@B29-ijerph-13-00642]\] presented both results of case-crossover and time-series, and estimates of time-series were included in overall analysis.

2.5. Additional Analysis {#sec2dot5-ijerph-13-00642}
------------------------

To evaluate the heterogeneity, we conducted a stratified analysis on study design (case-crossover and time-series), age (all and older than 65 years), outcome (hospitalization and mortality), and geographical location (Europe, North America, and Asia). In addition, we pooled estimates of PM~2.5~ and PM~10~ stratified by pollutant concentrations as defined by the World Health Organization (WHO) air quality guidelines (AQG) \[[@B30-ijerph-13-00642]\]. Based on the distribution of particulate concentrations in the included studies, the AQG of 24-h concentrations and interim target-3 of annual mean concentrations were selected as stratification levels. The population attributable risks (PARs) on RRs of the overall analysis were calculated using the following formula \[[@B31-ijerph-13-00642]\]. PARs indicate the fraction of health outcome that can be attributed to exposure in a given population. In the formula, P~e~ represents the prevalence of air pollution exposure, and we assumed that P~e~ is 100%: $$\text{Population} - \text{attributable~risks} = \frac{P_{\text{e}}\left( {\text{RR} - 1} \right)}{P_{\text{e}}\left( {\text{RR} - 1} \right) + 1}$$

2.6. Quality Assessment {#sec2dot6-ijerph-13-00642}
-----------------------

There is no standardized scale assessing the methodological quality of this type study. Therefore, we adopted a scale from related meta-analysis, which is composed of three items: validation of arrhythmia, exposure assessment, and adjustment of confounders \[[@B14-ijerph-13-00642]\].

### 2.6.1. Validation of Arrhythmia {#sec2dot6dot1-ijerph-13-00642}

The diagnosis of arrhythmia is coded according to International Classification of Diseases (ICD)-9, or ICD-10, or is based on clinical and laboratory information.

### 2.6.2. Exposure Assessment {#sec2dot6dot2-ijerph-13-00642}

The quality of pollutant measurement was assessed by measurement frequency. If it was conducted at least daily, we considered the study at low risk of bias. Otherwise, it was considered at high risk of bias.

### 2.6.3. Adjustment of Confounders {#sec2dot6dot3-ijerph-13-00642}

Meteorological parameters, time trends, influenza epidemics, and seasonality are four items used to assess the adjustment of confounders. Studies adjusting at least three items were considered at low risk of bias.

2.7. Statistical Analysis {#sec2dot7-ijerph-13-00642}
-------------------------

We anticipated significant heterogeneity between studies due to different study designs and locations. Therefore, random-effects model was performed. Heterogeneity between trials was assessed by the Chi‑square test and the extent of inconsistency was evaluated by the I^2^. Publication bias was assessed by Egger's regression test \[[@B32-ijerph-13-00642]\]. To evaluate the heterogeneity, additional analyses were performed by study design (case-crossover and time-series), age (all and older than 65 years), outcome (hospitalization and mortality), and geographical location (Europe, North America, and Asia). In addition, the PARs on RRs of the overall analysis were calculated to assess the fraction of arrhythmia attributed to exposure. Most studies presented estimates for single lags (for example: lag 0, lag 1 and lag 2). Single lags were pooled separately where more than three estimates were available. The shortest lag was used to evaluate overall risk estimates. In addition, a few studies only presented cumulative lags, which were not suitable in the single lag analysis. However, the estimates of cumulative lags were used in the overall analysis. RR per standardized increment in pollutant concentration with 95% confidence intervals (CIs) was presented for statistic. Our analysis was performed with Stata software (Version 12.0, StataCorp, College Station, TX, USA). Statistical significance was taken as a two sided *p* \< 0.05.

3. Results {#sec3-ijerph-13-00642}
==========

We initially identified 546 studies, and 75 studies were reviewed in depth. Ultimately, 25 studies \[[@B19-ijerph-13-00642],[@B20-ijerph-13-00642],[@B21-ijerph-13-00642],[@B22-ijerph-13-00642],[@B23-ijerph-13-00642],[@B27-ijerph-13-00642],[@B29-ijerph-13-00642],[@B33-ijerph-13-00642],[@B34-ijerph-13-00642],[@B35-ijerph-13-00642],[@B36-ijerph-13-00642],[@B37-ijerph-13-00642],[@B38-ijerph-13-00642],[@B39-ijerph-13-00642],[@B40-ijerph-13-00642],[@B41-ijerph-13-00642],[@B42-ijerph-13-00642],[@B43-ijerph-13-00642],[@B44-ijerph-13-00642],[@B45-ijerph-13-00642],[@B46-ijerph-13-00642],[@B47-ijerph-13-00642],[@B48-ijerph-13-00642],[@B49-ijerph-13-00642],[@B50-ijerph-13-00642]\] met the inclusion criteria ([Figure S1](#app1-ijerph-13-00642){ref-type="app"}). Of these 25 studies, 11 used a case-crossover design, 13 used a time-series design, and one study used both study designs. Our meta-analysis incorporated two million events ([Table S2, Table S3](#app1-ijerph-13-00642){ref-type="app"}). We excluded two of the 25 studies in the quantity analysis, one study \[[@B34-ijerph-13-00642]\] did not present original data and the other \[[@B49-ijerph-13-00642]\] did not report 95% CIs of the effect estimates. Nineteen of the 25 studies reported hospitalization as an outcome, five reported mortality, and one study both reported hospitalization and mortality.

3.1. Overall Analysis {#sec3dot1-ijerph-13-00642}
---------------------

Both particulate and gaseous components, with the exception of ozone, have a temporal association with arrhythmia hospitalization or mortality ([Figure S2](#app1-ijerph-13-00642){ref-type="app"}). In addition, generally only the overall and lag 0 associations were significant for PM~2.5~, PM~10~, CO, NO~2~, and SO~2~. PM~2.5~ and PM~10~ both showed increase (RR = 1.015, 95% CI: 1.006--1.024) and (RR = 1.009, 95% CI: 1.004--1.014) respectively per 10 μg/m^3^ increment. In addition, PM~2.5~ and PM~10~ were only positively associated with arrhythmia hospitalization or mortality on the event day. CO presented the strongest association. The increase was (RR = 1.041, 95% CI: 1.017--1.065) per 1 ppm increment. NO~2~ (RR = 1.036, 95% CI: 1.020--1.053) and SO~2~ (RR = 1.021, 95% CI: 1.003--1.039) were also positively associated with arrhythmia hospitalization or mortality per 10 ppb increment. However, O~3~ presented no association (RR = 1.012 per 10 ppb, 95% CI: 0.997--1.027) per 10 ppb increment.

3.2. Subgroup Analysis {#sec3dot2-ijerph-13-00642}
----------------------

The subgroup analysis results by age, outcome, study design and geographical location were consistent with the overall analysis for each pollutant, with the exception of SO~2~ ([Table 1](#ijerph-13-00642-t001){ref-type="table"}). The subgroup analysis of age and outcome *showed* no relation between SO~2~ and arrhythmia hospitalization or mortality.

Daily concentrations of air pollutants by geographical location are shown in [Table S4](#app1-ijerph-13-00642){ref-type="app"}. We observed that the concentrations of PM~2.5~ and PM~10~ in Asia were nearly 2- to 3-fold higher than those in the other two studied continents and compared with Europe and North America, Asia showed a stronger association across all pollutants.

3.3. Stratification by Background Concentrations {#sec3dot3-ijerph-13-00642}
------------------------------------------------

Twelve studies \[[@B23-ijerph-13-00642],[@B29-ijerph-13-00642],[@B33-ijerph-13-00642],[@B35-ijerph-13-00642],[@B36-ijerph-13-00642],[@B39-ijerph-13-00642],[@B40-ijerph-13-00642],[@B43-ijerph-13-00642],[@B44-ijerph-13-00642],[@B47-ijerph-13-00642],[@B48-ijerph-13-00642],[@B50-ijerph-13-00642]\] reported PM~10~. Studies ranking in the top three pollutant concentrations originated from developing countries (including China and Brazil). Pooled estimates showed that no association was found between PM~10~ and arrhythmia hospitalization or mortality (RR = 1.004 per 10 μg/m^3^, 95% CI: 0.992--1.017) in low concentrations (below 30 μg/m^3^).

However, PM~10~ was positively associated with arrhythmia at increased levels (30--50 μg/m^3^: RR = 1.016 per 10 μg/m^3^, 95% CI: 1.004--1.027; \>50 μg/m^3^: RR = 1.006 per 10 μg/m^3^, 95% CI: 1.004--1.007). A positive association was found between PM~2.5~ and arrhythmia hospitalization or mortality in all levels ([Table 2](#ijerph-13-00642-t002){ref-type="table"}).

3.4. Heterogeneity and Publication Bias {#sec3dot4-ijerph-13-00642}
---------------------------------------

Heterogeneity, publication bias and PARs are presented in [Table 3](#ijerph-13-00642-t003){ref-type="table"}. The heterogeneity across all pollutants was most evident for NO~2~ (*I*^2^ = 92.0%) and least evident for SO~2~ (*I*^2^ = 72.3%). The results of Egger's test illustrated that publication bias was noted for CO (*p* = 0.015).

4. Discussion {#sec4-ijerph-13-00642}
=============

The systematic review and meta-analysis showed that PM~2.5~, PM~10~, CO, NO~2~, and SO~2~ could increase the risk for arrhythmia hospitalization or mortality. Nevertheless, ozone had no association.

4.1. The Association between Air Pollution and Arrhythmia Maybe Stronger {#sec4dot1-ijerph-13-00642}
------------------------------------------------------------------------

Arrhythmia often shows no symptoms. Palpitations or feeling a pause between heartbeats are experienced in mild cases. Shortness of breath, light-headedness, syncope, or chest pain is reported in serious cases. Moreover, the majority of arrhythmia cases often lead to complications, such as heart failure, stroke or cardiac arrest \[[@B16-ijerph-13-00642]\]. Therefore, the number of hospitalizations and mortalities due to arrhythmia might be underestimated. Furthermore, data from monitoring stations might not represent personal exposure. The population density in the urban district is higher than that in the countryside. In addition, motor vehicle exhausts are an essential emission source contributing to air pollution \[[@B51-ijerph-13-00642]\]. Therefore, actual personal exposure might be higher.

4.2. Potential Mechanism between Arrhythmia and Air Pollution {#sec4dot2-ijerph-13-00642}
-------------------------------------------------------------

The mechanism of the association between arrhythmia and air pollution has not been fully understood. There are several possible reasons for the association. The first hypothesis is autonomic nervous system dysfunction \[[@B52-ijerph-13-00642],[@B53-ijerph-13-00642]\], which could lead to increased heart rate or decreased heart rate variability \[[@B54-ijerph-13-00642],[@B55-ijerph-13-00642]\]. This mechanism was thought to be the most plausible reason for the association. The second hypothesis is that air pollution may affect blood coagulability. Particles can cross the pulmonary epithelium into the bloodstream \[[@B56-ijerph-13-00642],[@B57-ijerph-13-00642]\]. The third hypothesis is inflammation \[[@B58-ijerph-13-00642]\]. Levels of inflammatory mediators would be higher due to air pollution \[[@B59-ijerph-13-00642]\].

4.3. Both Region and Pollutant Concentrations Affect Associations {#sec4dot3-ijerph-13-00642}
-----------------------------------------------------------------

Daily concentrations of PM~2.5~ and PM~10~ were higher in Asia, and both exceeded the recommend levels of WHO air quality guidelines (24-h concentrations: 25 μg/m^3^ and 50 μg/m^3^ respectively) \[[@B32-ijerph-13-00642]\]. Subgroup analysis on geographical location illustrated that increased risk of arrhythmia was found in Asia compared with Europe and North America. The additional analysis demonstrated that PM~10~ and arrhythmia are not associated at low pollutant concentrations. However, PM~10~ could elevate the risk of arrhythmia in increased concentrations. It indicates that the threshold for arrhythmia might be diverse in regions with varying pollutant concentrations. Research provides limited evidence on the threshold for adverse health effects. On the other hand, the thresholds for various types of diseases may be different. Therefore, the issue needs to be assessed further by more studies. Dose-response analyses and other type studies could provide evidence to identify the precise thresholds in different regions.

4.4. Implantable Cardioverter Defibrillator {#sec4dot4-ijerph-13-00642}
-------------------------------------------

With increasing attention being paid to health outcomes, numerous studies are focused on the health effects of air pollution. Hospitalization and mortality due to disease are the most commonly used health outcomes. Our study applied arrhythmia hospitalization or mortality as well. In terms of arrhythmia, some patients are equipped with the ICD. Studies have proven that ICD is effective in preventing sudden cardiac death for high-risk patients \[[@B60-ijerph-13-00642],[@B61-ijerph-13-00642]\]. In addition, ICD could continuously monitor arrhythmia and record the data and time of each episode. Therefore, many studies evaluated the relationship between arrhythmia detected by ICD and air pollution. Some have found a positive association between arrhythmia and air pollution, while others not \[[@B11-ijerph-13-00642],[@B62-ijerph-13-00642],[@B63-ijerph-13-00642],[@B64-ijerph-13-00642],[@B65-ijerph-13-00642],[@B66-ijerph-13-00642]\]. This needs to be confirmed further via large sample studies.

4.5. Significant Points for Further Research {#sec4dot5-ijerph-13-00642}
--------------------------------------------

Firstly, more attention should be paid to the association between disease and the components of air pollution. For instance, PM has attracted increasing concern especially since the haze outbreak in Beijing, China. During 2004 to 2008, the 24-h mean concentration of PM~2.5~ was 105 μg/m^3^ in Beijing, which was up to 4.2-fold higher than the recommended level reported by WHO guidelines \[[@B67-ijerph-13-00642]\]. On 7 December 2015, Beijing issued a red alert for heavy air pollution for the first time \[[@B68-ijerph-13-00642]\]. Nowadays, a considerable number of studies investigate PM, while studies researching the specific components of PM (such as endotoxin, cell fragments, iron, copper, nickel, zinc and vanadium) are limited \[[@B58-ijerph-13-00642],[@B69-ijerph-13-00642]\]. Moreover, it is significant to understand the mechanism between PM and diseases. Air pollution exposure assessments should also be improved. Outdoor concentrations could not assess personal exposure, particularly in cold seasons because people spend more time indoors \[[@B70-ijerph-13-00642],[@B71-ijerph-13-00642]\].

4.6. Limitations {#sec4dot6-ijerph-13-00642}
----------------

Potential limitations in our study need to be concerned. First, significant heterogeneities were observed in the analysis across all pollutants, possibly because data included in the meta-analysis came from five continents and several studies investigated the elderly population. Secondly, differences in study design and outcomes are also a potential source of heterogeneity. Thirdly, air pollution concentrations measured at monitoring sites likely caused misclassification bias for exposure, which is a common problem in environmental epidemiology. Finally, because most studies applied a single pollutant model instead of a multi-pollutant model, we assessed a single pollutant rather than multiple pollutants. To some extent, potential additive effects of multiple pollutants derived from the same emission source were ignored, such as motor vehicle exhausts and manufacturing.

4.7. Strengths {#sec4dot7-ijerph-13-00642}
--------------

Firstly, a meta-analysis and systematically review investigating the association between air pollution and arrhythmia published in any language has not been performed. Five major databases were comprehensively searched. PM~2.5~, PM~10~, CO, NO~2~, SO~2~ and O~3~ were all analyzed in our study. Secondly, the analysis of geographical locations yielded contrasting results amongst Europe, North America, and Asia, which provided some crucial suggestions for global air pollution governance. Finally, we pooled estimates of PM~2.5~ and PM~10~ stratified by pollutant concentrations, which provided some evidence for identifying the arrhythmia thresholds.

5. Conclusions {#sec5-ijerph-13-00642}
==============

Both particulate and gaseous components, with the exception of ozone, have a temporal association with arrhythmia hospitalization or mortality. The strongest associations were observed at the same day of exposure across all pollutants. In addition, a stronger association was noted in Asia, compared with Europe and North America. Pollutant concentrations should be considered in assessing the health effects of air pollution. A vast quantity of studies on health effects of air pollution have been conducted in developed countries. However, air pollution is a global issue. High quality studies are required in developing countries, which could contribute to making effective measurements globally.
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###### 

Subgroup analysis stratified by age, outcome, study design and geographical location across air pollutants.

  Subgroup Analysis       PM~2.5~ ^§^                  PM~10~                 CO \*                                                                                                                                                 
  ----------------------- ---------------------------- ---------------------- ---------------------- ---------------------------- ---------------------- ---------------------- ---------------------------- ---------------------- -------
  Age                                                                                                                                                                                                                               
     All                  15                           1.018 (1.007, 1.028)   79.8%                  9                            1.010 (1.003, 1.017)   82.5%                  8                            1.060 (1.017, 1.104)   91.9%
     ≥65 years            3                            1.009 (0.989, 1.028)   0                      2                            1.010 (1.002, 1.017)   0.0%                   3                            1.003 (0.982, 1.024)   0
  Outcome                                                                                                                                                                                                                           
     Hospitalization      17                           1.015 (1.005, 1.025)   78.4%                  12                           1.009 (1.004, 1.015)   79.7%                  12                           1.040 (1.017, 1.065)   90.9%
     Mortality            3                            1.027 (0.987, 1.068)   57.3%                  2                            1.009 (0.994, 1.024)   13.0%                  3                            1.077 (0.790, 1.467)   0
  Study Design                                                                                                                                                                                                                      
     Case Crossover       13                           1.017 (1.006, 1.028)   82.5%                  6                            1.012 (1.000, 1.024)   88.4%                  6                            1.076 (1.023, 1.133)   92.4%
     Time Series          6                            1.013 (1.003, 1.024)   0                      8                            1.006 (1.002, 1.011)   37.8%                  9                            1.026 (1.003, 1.050)   84.1%
  Geographical Location                                                                                                                                                                                                             
     Europe               2                            0.997 (0.972, 1.023)   57.1%                  3                            1.003 (0.992, 1.014)   80.6%                  3                            1.002 (1.000, 1.004)   0
     North America        12                           1.007 (1.003, 1.011)   0                      6                            1.009 (0.999, 1.019)   55.4%                  7                            1.032 (1.002, 1.063)   78.8%
     Asia                 5                            1.045 (1.011, 1.080)   85.2%                  4                            1.015 (1.003, 1.028)   88.8%                  2                            1.347 (1.236, 1.468)   30.8%
  **Subgroup Analysis**   **O~3~^\#^**                 **NO~2~^¢^**           **SO~2~^¶^**                                                                                                                                          
  **No. of Estimates**    **Relative Risk (95% CI)**   ***I*^2^**             **No. of Estimates**   **Relative Risk (95% CI)**   ***I*^2^**             **No. of Estimates**   **Relative Risk (95% CI)**   ***I*^2^**             
  Age                                                                                                                                                                                                                               
     All                  8                            1.019 (0.999, 1.039)   87.6%                  9                            1.037 (1.014, 1.061)   94.8%                  9                            1.018 (0.998, 1.037)   77.5%
     ≥65 years            2                            0.993 (0.969, 1.017)   0                      3                            1.023 (1.003, 1.042)   0.0%                   3                            1.047 (0.985, 1.113)   33.5%
  Outcome                                                                                                                                                                                                                           
     Hospitalization      9                            1.016 (0.997, 1.035)   85.4%                  13                           1.036 (1.018, 1.055)   93.5%                  10                           1.020 (1.000, 1.040)   77.1%
     Mortality            3                            0.997 (0.975, 1.018)   55.4%                  4                            1.026 (1.003, 1.050)   23.6%                  3                            1.028 (0.988, 1.069)   0
  Study Design                                                                                                                                                                                                                      
     Case Crossover       4                            1.037 (0.997, 1.078)   94.1%                  7                            1.059 (1.027, 1.093)   91.4%                  4                            1.002 (0.989, 1.016)   0
     Time Series          8                            1.003 (0.996, 1.010)   0                      10                           1.021 (1.003, 1.040)   92.6%                  9                            1.022 (1.002, 1.042)   79.6%
  Geographical Location                                                                                                                                                                                                             
     Europe               3                            1.002 (0.991, 1.014)   65.1%                  4                            1.016 (1.003, 1.030)   40.4%                  3                            1.010 (0.999, 1.021)   0
     North America        6                            0.998 (0.989, 1.008)   0                      7                            1.015 (1.003, 1.027)   66.3%                  6                            1.009 (0.992, 1.027)   32.4%
     Asia                 2                            1.086 (1.033, 1.141)   69.6%                  3                            1.099 (1.044, 1.158)   90.6%                  3                            1.060 (1.043, 1.077)   0

**^§^** PM: Particulate Matter; **\*** CO: Carbon Monoxide; **^\#^** O~3~: Ozone; **^¢^** NO~2~: Nitrogen Dioxide; **^¶^** SO~2~: Sulfur Dioxide; **^△^** *I*^2^: Inconsistency Index.
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###### 

Association between particulate matter (PM~2.5~ and PM~10)~ and hospitalization or mortality due to arrhythmia stratified by pollutant concentrations.

  Selected Levels          No. of Estimates   Relative Risk (95% CI \*)   *I*^2△^
  ------------------------ ------------------ --------------------------- ---------
  PM~2.5~ ^¶^                                                             
  ～15 μg/m^3^             12                 1.005 (1.001, 1.009)        0
  15 μg/m^3^--25 μg/m^3^   3                  1.019 (1.006, 1.033)        0
  25 μg/m^3^～             4                  1.053 (1.012, 1.094)        87.4%
  PM~10~                                                                  
  ～30 μg/m^3^             5                  1.004 (0.992, 1.017)        69.6%
  30 μg/m^3^--50 μg/m^3^   6                  1.016 (1.004, 1.027)        84.0%
  50 μg/m^3^～             2                  1.006 (1.004, 1.007)        0

**^¶^** PM: Particulate Matter; **^△^** *I*^2^: Inconsistency Index.

ijerph-13-00642-t003_Table 3

###### 

Heterogeneity, publication bias and population attributable risks across air pollutants.

  Item                                PM~2.5~ (μg/m^3^) ^¶^   PM~10~ (μg/m^3^)       CO (ppm)               Ozone (ppb)             NO~2~ (ppb)            SO~2~ (ppb)
  ----------------------------------- ----------------------- ---------------------- ---------------------- ----------------------- ---------------------- ----------------------
  Increment                           10                      10                     1                      10                      10                     10
  No. of estimates                    19                      13                     14                     11                      16                     12
  No. of studies                      11                      12                     12                     10                      14                     11
  Pollutant concentration:                                                                                                                                 
  Median                              15.272                  30.737                 1.021                  23.793                  24.885                 4.038
  Q1--Q3 **^\#^**                     9.860--21.425           21.530--48.222         0.702--1.438           15.976--33.165          18.464--31.951         2.333--9.257
  Heterogeneity                       75.70%                  77.80%                 89.40%                 82.60%                  92%                    72.30%
  RR (95% CI) **\***                  1.015 (1.006, 1.024)    1.009 (1.004, 1.014)   1.041 (1.017, 1.065)   1.012 (0.997, 1.027)    1.036 (1.020, 1.053)   1.021 (1.003, 1.039)
  *p* value **^§^**                   0.001                   0.001                  0.001                  0.115                   \<0.001                0.025
  Egger regression test (*p* value)   0.132                   0.365                  0.015                  0.305                   0.726                  0.555
  PARs (95% CI) **^¢^**               0.015 (0.006, 0.023)    0.009 (0.004, 0.014)   0.039 (0.017, 0.061)   0.012 (−0.003, 0.026)   0.035 (0.020, 0.050)   0.021 (0.003, 0.038)

**\*** Risk estimates of overall analysis across air pollutants. **^§^** *p* value: *p* value of overall analysis across air pollutants. **^¢^** PARs (population attributable risks) = P~e~ (RR − 1)/(P~e~(RR − 1) + 1).**^¶^** PM: Particulate Matter. **^\#^** Q1: first quartile value. Q3: third quartile value. ppm: parts per million. ppb: parts per billion.
